Objectives: At the end of this program, participants should be able to:
1. Review the biologic rationale, related to the role of RhoKinase (ROCK) ignaling in CA pathogenesis and the use of atorvastatin as a ROCK inhibitor.
2. Expalin QSM and DCEQP imaging as biomarkers of CA iron deposit and vascular leak, linked to clinical activity.
3. Describe the approved Phase I-IIa proof of concept clinical trial, with emphasis on design innovations, and go-no go implications.
07/11/2018 - 8:30am to 9:30am CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Sean Polster, MD